PRS

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

Retrieved on: 
Monday, November 20, 2023
NDA, Pancreatic cancer, Safety, Research, NCCN, Sickle cell disease, ASH, Liver, Clinical trial, Patient, PRS, Natalizumab, FDA, Marketing, PDAC, G&A, Conference, Partnership, EST, Biomarker, Columbia University, Society, TEL, BioLineRx, GENESIS, Poster, TASE, AACR, Pharmaceutical industry, Rare-earth element, Cryptocurrency

- Management to host conference call today, November 20, at 10:00 a.m. EST -

Key Points: 
  • - Management to host conference call today, November 20, at 10:00 a.m. EST -
    TEL AVIV, Israel, Nov. 20, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the third quarter ended September 30, 2023, and provided corporate and portfolio updates.
  • "In addition, the company also closed its motixafortide licensing agreement covering the important Asia market.
  • The highly encouraging data triggered a change in the protocol, from a small, single-arm study to a much larger randomized study.
  • A dial-in replay of the call will be available until November 22, 2023; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Neoplasm, Research, PRS, Carboplatin, Ovarian cancer, Trae Waynes, Traveller Alien Module 2: K'kree, Oncology nursing, Partnership, CBR, September 5, ATR, CCNE1, Circulating tumor DNA, OR, BMS, Paclitaxel, Ono, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Glomus tumor, Roche, Net, Safety, Therapy, Cancer, Patient, DNA, MRR, Conference, Clinical trial, Anemia, IST, AACR, Red Barricades: ASL Historical Module 1, FOLFIRI, Genotype, PPP2R1A, PKMYT1, FBXW7, Princess Margaret Cancer Centre, RECIST, Modularity, PARP, Pharmaceutical industry, Vaccine, Reinsurance, Reparenting, G&A, IND

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.
  • In the cohort of patients with gynecologic tumors, the RECIST response was 50%, OR was 60%, and CBR was 70%.
  • These patients also had a median of 3 and up to 9 prior lines of therapy, before administration of lunresertib.
  • RP-3467 is Repare’s wholly-owned Polθ inhibitor, currently in IND-enabling studies, which began in the second quarter of 2023 and remain ongoing.

Study demonstrates clinical utility of polygenic risk scores for cardiovascular disease in multiple ancestries

Retrieved on: 
Thursday, November 9, 2023
PRS, Laboratory, United Kingdom, CAD, Genetic testing, Genetics, CAP, Coronary artery disease, Research, CLIA, Genomics, Disease, Risk, Nature Communications, LDL, Medicine, Partnership, Patient, Cardiovascular disease, Pharmaceutical industry, Medical device

NEW YORK, Nov. 9, 2023 /PRNewswire/ --Allelica, a leading provider of clinical bioinformatics technology, has announced its scientific team's publication of their latest research in Nature Communications. The publication, "Ancestry-specific polygenic risk scores are risk enhancers for clinical cardiovascular disease assessments", builds on the company's ongoing efforts to make polygenic risk scores (PRSs) for coronary artery disease (CAD) accessible in healthcare settings for individuals of all ancestries. This research marks a significant milestone in Allelica's mission to revolutionize healthcare by harnessing the power of PRS. 

Key Points: 
  • The publication, "Ancestry-specific polygenic risk scores are risk enhancers for clinical cardiovascular disease assessments", builds on the company's ongoing efforts to make polygenic risk scores (PRSs) for coronary artery disease (CAD) accessible in healthcare settings for individuals of all ancestries.
  • Key findings of the publication include:
    Allelica's CAD PRSs identify individuals at high genetic risk of disease across all major genetic ancestry groups.
  • Using high CAD PRS as a risk factor leads to more accurate clinical risk assessments compared to models that don't use genetic information.
  • Our results highlight the transformative potential of polygenic risk scores to identify this risk and use it in clinical risk assessments for one of the most common, and preventable diseases - coronary artery disease.

AI-Accelerated Productivity Surge: Turing Unveils a Significant 25% Boost in Software Development Acceleration Through AI-Assisted Experiment

Retrieved on: 
Wednesday, November 8, 2023
Cloud, PRS, LOC, Engineering, Meta, Group C, Cognizant, Synthetic media, Group A, PALO, Entrepreneurship, Data, GPT, Software, Growth, Group B, Lincoln L-head V12 engine, Machine learning, AI, Medical device, Sales, Alan Turing

PALO ALTO, Calif., Nov. 8, 2023 /PRNewswire/ -- Turing, the world's first AI-powered tech services company, today announced the results of its AI-accelerated software development study. The company's experiment, conducted with various Generative AI tools since May, underscores the rapidly evolving technology as a high-impact efficiency and productivity tool for developers and reveals its potential to usher in a fundamental shift in the dynamics between technology and human expertise. The findings of Turing's AI-accelerated development experiment have yielded a 25% average increase in developer productivity, demonstrating generative AI's significant impact on accelerating software project delivery and overall product innovation cycles. The results also show productivity improvement continues over time, indicating generative AI's long-term impact.

Key Points: 
  • PALO ALTO, Calif., Nov. 8, 2023 /PRNewswire/ -- Turing, the world's first AI-powered tech services company, today announced the results of its AI-accelerated software development study.
  • The findings of Turing's AI-accelerated development experiment have yielded a 25% average increase in developer productivity, demonstrating generative AI's significant impact on accelerating software project delivery and overall product innovation cycles.
  • The results also show productivity improvement continues over time, indicating generative AI's long-term impact.
  • "The software development landscape is evolving, with AI enhancing rather than replacing the central role of engineers," said Jonathan Siddharth, Turing's CEO and Co-Founder.

Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance

Retrieved on: 
Monday, November 6, 2023
PRS, UnitedHealth Group, Memorial Sloan Kettering Cancer Center, Cancer, Policy, ARR, Genetic testing, Patent, MDD, CDX, Radiation, Myriad Genetics, Family, Physician, DSM-IV codes, Genetics, Prostate cancer, MSK, GAAP, Research, ADT, Circulating tumor DNA, Metabolism, Meta-analysis, Ravgen, MRD, Women's health, Biopsy, Breast cancer, Risk assessment, Breast, Woman, Depression, ABL, Anxiety, Google Images, Attention deficit hyperactivity disorder, Neoplasm, Metastasis, DNA, Video game, Medical imaging, Pharmaceutical industry, Vaccine, Dietary supplement, Birth control, Medical device, Bank, Risk, Patient, Oncology

SALT LAKE CITY, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2023. The Company also provided an update on its business performance and 2023 financial guidance.

Key Points: 
  • GAAP gross margins of 70.0% in the third quarter of 2023; adjusted gross margins for the third quarter of 2023 was 70.4%, an increase of 140.0 basis points from the second quarter of 2023.
  • The Myriad Genetics Oncology business provides hereditary cancer testing, including the MyRisk® hereditary cancer test for patients who have cancer.
  • Prolaris continued to see healthy demand as third quarter testing revenue and volumes grew 18% and 9% year-over-year, respectively.
  • 16_suppl (June 01, 2023)5030
    Myriad Genetics updates its 2023 revenue and non-GAAP financial guidance, as stated in the table below.

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 6, 2023
Diamond, TKI, Patient, NRAS, FDA, Survival, PRS, Research, NSCLC, AACR, GBM, Aes, Food, Infrared spectroscopy correlation table, MAPK, G&A, Conference, CNS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, RAF, Poster, DNA, Development, Allele, BRAF, M26 Modular Accessory Shotgun System, Clinical trial, Neoplasm, Cancer, ORR, RECIST, Waikato District Health Board ransomware attack, Lung cancer, Investment, Therapy, Administration, Mutation, EGFR, State Administrative Expenses, Black Diamond, Medical imaging, Life insurance, Pharmaceutical industry

and NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points: 
  • and NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • In October 2023, Black Diamond presented a poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics detailing preclinical data for BDTX-4933.
  • In September 2023, Black Diamond announced a CEO transition, appointing Chairman of the Board Mark Velleca, M.D., Ph.D. to President and Chief Executive Officer.
  • Net cash used in operations was $18.4 million for the third quarter of 2023 compared to $16.5 million for the third quarter of 2022.

Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, November 2, 2023
Research, PRS, AACR, Genentech, Conference, Investment, Triple, Clinical trial, Breast cancer, Therapy, Patient, Fulvestrant, D, Pharmaceutical industry, Birth control

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported third quarter 2023 financial results and corporate highlights.

Key Points: 
  • Approximately $811 million in cash, cash equivalents and investments at end of Q3 2023, expected to fund operations into second half of 2026
    CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported third quarter 2023 financial results and corporate highlights.
  • Relay Therapeutics expects its current cash, cash equivalents and investments will be sufficient to fund its current operating plan into the second half of 2026.
  • Revenue: Revenue was $25.2 million for the third quarter of 2023, as compared to $0.3 million for the third quarter of 2022.
  • G&A Expenses: General and administrative expenses were $18.5 million for the third quarter of 2023, as compared to $16.1 million for the third quarter of 2022.

3D Systems Introduces New Materials & Technologies Designed to Address Broader Application Portfolio at Formnext 2023

Retrieved on: 
Wednesday, November 1, 2023
Niobium, SLS, PRS, 3D, DDP, RPM, Digital, HX, Powder, ROCK, NYSE, Temperature, AN/SEQ-3 Laser Weapon System, Stainless steel, Food, HDT, 3D Systems, Pressure, 300C, Future Affordable Turbine Engine, Revolutions per minute, Laser, Printing, AMX, Seamless, AIG, SLA, SAE 316L stainless steel, Flexible impeller, Spacecraft, Workflow, HEPA, CP1, HVAC, DMP, NASA, Defense, Chemistry, 3D printing, Video game, Extrusion, Turnkey

SLS 300 Expands Selective Laser Sintering Portfolio with Affordable, Turnkey, Closed-loop System

Key Points: 
  • SLS 300 Expands Selective Laser Sintering Portfolio with Affordable, Turnkey, Closed-loop System
    At Formnext, 3D Systems is formally introducing the SLS 300 (formerly the Wematter Gravity).
  • In its booth at Formnext, 3D Systems will introduce the new SLS 300 Powder Recycling Station (PRS).
  • At Formnext 2023, 3D Systems will preview the PSLA 270, a new projector-based polymer 3D printing platform.
  • Formnext attendees are encouraged to visit 3D Systems’ booth to learn more and provide early feedback on this game-changing solution.

Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability

Retrieved on: 
Friday, November 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Society for Immunotherapy of Cancer, Neoplasm, Patient, FRCP, MDSC, PRS, NSCLC, Poster, PD, Aes, UC, Publication, Vomiting, DCR, Diarrhea, Pembrolizumab, Metastasis, Associate professor, Safety, Conference, Doctor of Philosophy, MBBS, Data, Nausea, CD8, Rash, Cancer immunotherapy, Immunotherapy, Rock, SD, DRAGON, SITC, San Diego Convention Center, Biopsy, Annual general meeting, ORR, University, RECIST, Biomarker, Melanoma, Lung cancer, Society, Therapy, AE, Carcinoma, Spectrochimica Acta Part B, Dermatitis, PR, Toxic epidermal necrolysis, Pharmaceutical industry, Medical imaging, Nightclub, Part

The second poster focuses on preliminary biomarker data from part B of the trial in patients with multiple tumor types.

Key Points: 
  • The second poster focuses on preliminary biomarker data from part B of the trial in patients with multiple tumor types.
  • Data presented continues to support proof of concept for SRK-181 in 28 heavily pretreated patients with ccRCC resistant to anti-PD-1.
  • In the biomarker analysis for ccRCC, levels of circulating granulocytic myeloid-derived suppressor cells (gMDSC) correlated with clinical activity in ccRCC patients treated with SRK-181 in combination with pembrolizumab.
  • “The DRAGON trial has successfully delivered on its objective of demonstrating proof of concept for SRK-181 by showing promising anti-tumor activity.

IDRx Presents Preliminary Clinical Data from Ongoing Phase 1 StrateGIST Study at CTOS 2023 Supporting Best-in-Class Potential of IDRX-42 in Patients with GIST

Retrieved on: 
Thursday, November 2, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, TKI, Patient, KIT, PRS, MTD, MPH, Physician, BID, Exon, Poster, Strategist, UZ Leuven, Annual general meeting, GIST, RECIST, Stromal cell, Therapeutic index, Pharmaceutical industry, MD

“Importantly, these preliminary data will help guide our discussions with physicians regarding development strategies for IDRX-42 in patients with GIST in early lines of therapy to prevent the emergence of genomically-driven resistance mutations.

Key Points: 
  • “Importantly, these preliminary data will help guide our discussions with physicians regarding development strategies for IDRX-42 in patients with GIST in early lines of therapy to prevent the emergence of genomically-driven resistance mutations.
  • Median duration on treatment was 16 weeks and continuing, with 70% (23/33) of patients remaining on treatment at time of data cutoff.
  • 4/28 patients are on study for
  • Title: Phase 1 Study of IDRX-42 in Patients with Advanced Gastrointestinal Stromal Tumors Resistant to Prior Systemic Therapy: Early Results
    Session: CTOS Poster Reception 5:30-6:30 p.m. GMT, Thursday, November 2nd